AcelRx Pharma (ACRX) – PRNewswire
-
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
-
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
-
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
-
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
-
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
-
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
-
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
-
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
-
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
-
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
-
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
-
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
-
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
-
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
-
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
-
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022
-
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022
-
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant
-
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANE
-
AcelRx Pharmaceuticals Announces Reverse Stock Split
-
AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
-
AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
-
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022
-
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
-
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
-
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
-
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Proce
-
AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022
-
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022
-
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
-
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
-
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
-
AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
-
AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet
-
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surger
-
AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
Back to ACRX Stock Lookup